(NASDAQ: ENTA) Enanta Pharmaceuticals's forecast annual revenue growth rate of 1% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 117.62%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.18%.
Enanta Pharmaceuticals's revenue in 2026 is $66,980,000.On average, 9 Wall Street analysts forecast ENTA's revenue for 2026 to be $1,914,493,182, with the lowest ENTA revenue forecast at $1,663,678,992, and the highest ENTA revenue forecast at $2,160,345,064. On average, 7 Wall Street analysts forecast ENTA's revenue for 2027 to be $1,918,120,600, with the lowest ENTA revenue forecast at $1,558,745,044, and the highest ENTA revenue forecast at $2,346,213,962.
In 2028, ENTA is forecast to generate $2,022,300,045 in revenue, with the lowest revenue forecast at $1,356,102,964 and the highest revenue forecast at $2,986,090,498.